RC18 240 mg ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
11	Myasthenia gravis	1
53	Sjogren syndrome	1

11. Myasthenia gravis

---

Clinical trials : 332 /  Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04302103 (ClinicalTrials.gov)	July 23, 2020	6/3/2020	A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis	A Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Systemic Myasthenia Gravis	Systemic Myasthenia Gravis	Biological: RC18 160mg;Biological: RC18 240 mg	RemeGen Co., Ltd.	NULL	Active, not recruiting	18 Years	70 Years	All	29	Phase 2	China

53. Sjogren syndrome

---

Clinical trials : 305 /  Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04078386 (ClinicalTrials.gov)	November 21, 2019	18/7/2019	A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome	A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg	RemeGen Co., Ltd.	NULL	Completed	18 Years	65 Years	All	42	Phase 2	China